Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Antiangiogenic therapy in oncology: current status and future directions.

Jayson GC, Kerbel R, Ellis LM, Harris AL.

Lancet. 2016 Feb 4. pii: S0140-6736(15)01088-0. doi: 10.1016/S0140-6736(15)01088-0. [Epub ahead of print] Review.

PMID:
26853587
2.

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.

Wang R, Ye X, Bhattacharya R, Boulbes DR, Fan F, Xia L, Ellis LM.

Stem Cells Transl Med. 2016 Mar;5(3):331-8. doi: 10.5966/sctm.2015-0168. Epub 2016 Jan 7.

PMID:
26744411
3.

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ.

J Clin Oncol. 2015 Nov 1;33(31):3583-90. doi: 10.1200/JCO.2015.62.4148. Epub 2015 Aug 24.

PMID:
26304898
4.

CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.

Camp ER, Ellis LM.

Clin Cancer Res. 2015 Aug 15;21(16):3578-80. doi: 10.1158/1078-0432.CCR-14-2900.

PMID:
26275951
5.

Losing "Losing the Battle With Cancer".

Ellis LM, Blanke CD, Roach N.

JAMA Oncol. 2015 Apr;1(1):13-4. doi: 10.1001/jamaoncol.2014.188. No abstract available.

PMID:
26182295
6.

The erosion of research integrity: the need for culture change.

Ellis LM.

Lancet Oncol. 2015 Jul;16(7):752-4. doi: 10.1016/S1470-2045(15)00085-6. Review. No abstract available.

PMID:
26149871
7.

VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

Ye X, Fan F, Bhattacharya R, Bellister S, Boulbes DR, Wang R, Xia L, Ivan C, Zheng X, Calin GA, Wang J, Lu X, Ellis LM.

Mol Cancer Res. 2015 Sep;13(9):1274-82. doi: 10.1158/1541-7786.MCR-15-0061. Epub 2015 Jun 3.

PMID:
26041938
8.

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X.

Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22.

9.

Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.

Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S.

Clin Cancer Res. 2015 Feb 15;21(4):899-906. doi: 10.1158/1078-0432.CCR-14-0894. Epub 2014 Dec 16.

10.

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR.

Nat Rev Clin Oncol. 2015 Apr;12(4):197-212. doi: 10.1038/nrclinonc.2014.202. Epub 2014 Nov 25. Review.

PMID:
25421275
11.

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS.

Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14.

12.

Therapeutic silencing of KRAS using systemically delivered siRNAs.

Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK.

Mol Cancer Ther. 2014 Dec;13(12):2876-85. doi: 10.1158/1535-7163.MCT-14-0074. Epub 2014 Oct 3.

13.

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Review.

14.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE.

J Clin Oncol. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17. No abstract available.

15.

Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G.

Clin Cancer Res. 2014 Feb 15;20(4):837-46. doi: 10.1158/1078-0432.CCR-13-1854. Epub 2013 Dec 9.

16.

Analysis of LGR4 receptor distribution in human and mouse tissues.

Yi J, Xiong W, Gong X, Bellister S, Ellis LM, Liu Q.

PLoS One. 2013 Oct 21;8(10):e78144. doi: 10.1371/journal.pone.0078144. eCollection 2013.

17.

miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.

Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, Calin GA, Ellis LM, Lu X.

Mol Oncol. 2014 Feb;8(1):83-92. doi: 10.1016/j.molonc.2013.09.004. Epub 2013 Oct 8.

18.

Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells.

Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B.

PLoS One. 2013 Oct 15;8(10):e77398. doi: 10.1371/journal.pone.0077398. eCollection 2013.

19.

ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.

Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z.

Mol Cancer Ther. 2013 Dec;12(12):2782-91. doi: 10.1158/1535-7163.MCT-13-0098. Epub 2013 Oct 16.

20.

An audience with : Lee M. Ellis. Interviewd by Man Tsuey Tse.

Ellis LM.

Nat Rev Drug Discov. 2013 Aug;12(8):572-3. doi: 10.1038/nrd4085. Epub 2013 Jul 19. No abstract available.

PMID:
23868111
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk